Next Article in Journal
Low-Level Laser Therapy with a 635 nm Diode Laser Affects Orthodontic Mini-Implants Stability: A Randomized Clinical Split-Mouth Trial
Next Article in Special Issue
Fenofibrate Facilitates Post-Active Tuberculosis Infection in Macrophages and is Associated with Higher Mortality in Patients under Long-Term Treatment
Previous Article in Journal
Antibacterial Activity of Some Flavonoids and Organic Acids Widely Distributed in Plants
Previous Article in Special Issue
Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy

Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update

FIND, 1202 Geneva, Switzerland
International Clinical Research Center, University of Washington, Seattle, WA 98105, USA
Institute of Disease Modeling, Bellevue, WA 98005, USA
Department of Laboratory Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
Division of Tropical Medicine, Center of Infectious Diseases, University of Heidelberg, 69120 Heidelberg, Germany
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(1), 111;
Received: 30 November 2019 / Revised: 24 December 2019 / Accepted: 25 December 2019 / Published: 31 December 2019
(This article belongs to the Special Issue Tuberculosis: Clinical Applications in the Diagnosis and Treatment)
Most diagnostic tests for tuberculosis (TB) rely on sputum samples, which are difficult to obtain and have low sensitivity in immunocompromised patients, patients with disseminated TB, and children, delaying treatment initiation. The World Health Organization (WHO) calls for the development of a rapid, biomarker-based, non-sputum test capable of detecting all forms of TB at the point-of-care to enable immediate treatment initiation. Lipoarabinomannan (LAM) is the only WHO-endorsed TB biomarker that can be detected in urine, an easily collected sample. This status update discusses the characteristics of LAM as a biomarker, describes the performance of first-generation urine LAM tests and reasons for slow uptake, and presents considerations for developing the next generation of more sensitive and impactful tests. Next-generation urine LAM tests have the potential to reach adult and pediatric patients regardless of HIV status or site of infection and facilitate global TB control. Implementation and scale-up of existing LAM tests and development of next-generation assays should be prioritized. View Full-Text
Keywords: Tuberculosis (TB); diagnostics; Lipoarabinomannan (LAM); urinary tests Tuberculosis (TB); diagnostics; Lipoarabinomannan (LAM); urinary tests
Show Figures

Graphical abstract

  • Externally hosted supplementary file 1
    Doi: 10.20944/preprints201912.0002.v1
MDPI and ACS Style

Bulterys, M.A.; Wagner, B.; Redard-Jacot, M.; Suresh, A.; Pollock, N.R.; Moreau, E.; Denkinger, C.M.; Drain, P.K.; Broger, T. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. J. Clin. Med. 2020, 9, 111.

AMA Style

Bulterys MA, Wagner B, Redard-Jacot M, Suresh A, Pollock NR, Moreau E, Denkinger CM, Drain PK, Broger T. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. Journal of Clinical Medicine. 2020; 9(1):111.

Chicago/Turabian Style

Bulterys, Michelle A., Bradley Wagner, Maël Redard-Jacot, Anita Suresh, Nira R. Pollock, Emmanuel Moreau, Claudia M. Denkinger, Paul K. Drain, and Tobias Broger. 2020. "Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update" Journal of Clinical Medicine 9, no. 1: 111.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop